BIOCRATES Life Sciences AG
Biocrates and Metanomics Health have recently merged to create a new global leader in Metabolomics and early disease detection. As a total solution provider, Biocrates and Metanomics Health provide the broadest technology and product portfolio in the industry. The merged companies have extensive expertise in targeted and global metabolic profiling, customized assay development, targeted screening kits, and data interpretation. Finally, capabilities in CDx / Diagnostic Kit development make Biocrates and Metanomics Health the preferred partner for all its costumers’ requirements in metabolite analysis. Biocrates’ metabolomics kits allow for the analysis of up to 500 metabolites across multiple analyte classes in a single run. The whole range of analytical and data interpretation services is available through the company’s service laboratories in Berlin, Germany and Innsbruck, Austria.